PharmaSGP Holding SE (PSG) - Total Liabilities
Based on the latest financial reports, PharmaSGP Holding SE (PSG) has total liabilities worth €81.51 Million EUR (≈ $95.29 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PharmaSGP Holding SE cash flow conversion to assess how effectively this company generates cash.
PharmaSGP Holding SE - Total Liabilities Trend (2014–2024)
This chart illustrates how PharmaSGP Holding SE's total liabilities have evolved over time, based on quarterly financial data. Check PharmaSGP Holding SE liquid asset ratio to evaluate the company's liquid asset resilience ratio.
PharmaSGP Holding SE Competitors by Total Liabilities
The table below lists competitors of PharmaSGP Holding SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Danal Co. Ltd
KQ:064260
|
Korea | ₩519.07 Billion |
|
Test Rite International Co Ltd
TW:2908
|
Taiwan | NT$29.27 Billion |
|
Tatva Chintan Pharma Chem Limited
NSE:TATVA
|
India | Rs1.53 Billion |
|
Fusion Micro Finance Limited
NSE:FUSION
|
India | Rs54.19 Billion |
|
Suzhou Shijing Environmental Technology Co.Ltd.
SHE:301030
|
China | CN¥8.76 Billion |
|
Kits Eyecare Ltd
TO:KITS
|
Canada | CA$36.85 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down PharmaSGP Holding SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PharmaSGP Holding SE market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaSGP Holding SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaSGP Holding SE (2014–2024)
The table below shows the annual total liabilities of PharmaSGP Holding SE from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €82.31 Million ≈ $96.23 Million |
-10.09% |
| 2023-12-31 | €91.55 Million ≈ $107.03 Million |
-6.60% |
| 2022-12-31 | €98.01 Million ≈ $114.59 Million |
+5.32% |
| 2021-12-31 | €93.06 Million ≈ $108.80 Million |
+592.58% |
| 2020-12-31 | €13.44 Million ≈ $15.71 Million |
+64.65% |
| 2019-12-31 | €8.16 Million ≈ $9.54 Million |
-63.05% |
| 2017-12-31 | €22.09 Million ≈ $25.82 Million |
-1.69% |
| 2016-12-31 | €22.47 Million ≈ $26.27 Million |
-4.22% |
| 2015-12-31 | €23.46 Million ≈ $27.42 Million |
+16.53% |
| 2014-12-31 | €20.13 Million ≈ $23.53 Million |
-- |
About PharmaSGP Holding SE
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil … Read more